ProfileGDS5678 / 1440777_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 32% 32% 30% 31% 33% 31% 30% 32% 33% 32% 30% 54% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8263435
GSM967853U87-EV human glioblastoma xenograft - Control 22.7280732
GSM967854U87-EV human glioblastoma xenograft - Control 32.7321532
GSM967855U87-EV human glioblastoma xenograft - Control 42.6313430
GSM967856U87-EV human glioblastoma xenograft - Control 52.658231
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8242233
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7550231
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6769830
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7038632
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7301533
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7169832
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6585530
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3519454
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7262832